Diabetes company sees potential in Russia

According to recent report, the Danish pharmaceutical group Novo Nordisk foresees large growth in the insulin market in Russia, mirroring what has happened in China in recent years.
Novo, who have hit diabetes headlines recently due to their pledge to help children in developing countries manage type 1 diabetes, foresee major expansion into the Russian market in the next few years.
More and more people are being diagnosed with type 2 diabetes in Russia. Novo Chief Executive Lars Sorenson reportedly commented: “We expect growth rates in Russia of over 20 percent for a number of years into the future.”
According to Russian Diabetes Federation estimates, as many as 10 million people will be diagnosed with diabetes in Russia by 2025.